US-based medical technology provider Boston Scientific said it is launching the new polymer-based drug-eluting stent (DES) system in the European market as the product has obtained CE mark approval.
The Promus Premier everolimus-eluting platinum chromium stent system is used to treat patients with coronary artery disease.
The DES system, which is available in a matrix of 47 sizes, ranging in diameter from 2.25mm to 4mm and lengths of 8mm to 38mm on a Monorail catheter platform, is designed for keeping the coronary artery open and allowing the blood to flow more freely.
The DES system features a combination of everolimus drug and fluorinated co-polymer, and a customized Platinum Chromium (PtCr) stent architecture.
Mercy Angiography interventional cardiologist John Ormiston said, "The customized Platinum Chromium stent architecture maintains the superior visibility, exceptional radial strength and fracture resistance, minimal recoil and outstanding clinical outcomes of a PtCr Everolimus-Eluting stent while offering improved longitudinal strength."
According to Boston Scientific, the device includes a low-profile delivery system which features a shorter, more visible tip, a dual-layer balloon and a bi-segment inner lumen catheter to facilitate precise stent delivery across challenging lesions.
The company said the everolimus drug and fluorinated co-polymer stent coating have been studied in multiple randomized clinical trials including the Platinum Workhorse trial, which compared the Promus Element stent with the Xience V stent (cobalt chromium everolimus-eluting stent).
